Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 1b/2 EPCORE CLL-1 trial expansion cohort

被引：0
|
作者：
Kater, Arnon
Eradat, Herbert
Niemann, Carsten
Offner, Fritz
Poulsen, Christian Bjorn
Hoyer, Thor
Bellido, Mar
Shadman, Mazyar
Oki, Toshihiko
Kuznetsova, Alexandra
Rios, Marcia
Valentin, Rebecca
Bentzen, Hans Herluf
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1546171
引用
收藏
页码：S2 / S3
页数：2
相关论文
共 50 条
  • [1] Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial
    Kater, Arnon P.
    Christensen, Jacob Haaber
    Bentzen, Hans Herluf
    Niemann, Carsten Utoft
    Hutchings, Martin
    Chen, Jenny
    Rios, Marcia
    Palenski, Tammy
    Li, Tommy
    Mato, Anthony R.
    BLOOD, 2021, 138
  • [2] Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)
    Kater, Arnon P.
    Ye, J. Christine
    Sandoval-Sus, Jose
    Bellido, Mar
    Christensen, Jacob Haaber
    Mato, Anthony R.
    Janssens, Ann
    Oki, Toshihiko
    Hoehn, Daniela
    Rios, Marcia
    Kuznetsova, Alexandra
    Valentin, Rebecca
    Eradat, Herbert
    BLOOD, 2022, 140
  • [3] Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Jones, Jeffrey A.
    Woyach, Jennifer
    Awan, Farrukh T.
    Maddocks, Kami J.
    Whitlow, Thomas
    Ruppert, Amy S.
    Byrd, John C.
    BLOOD, 2016, 128 (22)
  • [4] Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial
    Kater, Arnon P.
    Janssens, Ann
    Eradat, Herbert
    Offner, Fritz
    Sandoval-Sus, Jose D.
    Shadman, Mazyar
    Poulsen, Christian Bjorn
    Christensen, Jacob Haaber
    Thompson, Meghan C.
    Rios, Marcia
    Kuznetsova, Alexandra
    Oki, Toshihiko
    Valentin, Rebecca
    Bellido, Mar
    Eichhorst, Barbara
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S350 - S351
  • [5] Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial
    Catherine, Thieblemont
    Tycel, Phillips
    Herve, Ghesquieres
    Cheah, Chan Y.
    David, Cunningham
    Do, Young R.
    Tatyana, Feldman
    Robin, Gasiorowski Robin
    Wojciech, Jurczak
    Tae, Min Kim Tae M.
    Lewis, David J.
    Mariolein, Van der Poe
    Poon, Michelle L.
    Thomas, Doerr
    Nurgul, Kilavuz
    Menghui, Chen
    Mariana, Sacchi
    Martin, Hutchings
    Pieternella, Lugtenburg
    Roost, Clausen Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S32
  • [6] Phase 1b Trial of Subcutaneous Epcoritamab in Pediatric Patients with Relapsed or Refractory (R/R) Aggressive Mature B-Cell Neoplasms (EPCORE Peds-1)
    Cairo, Mitchell S.
    Rocco, Mark A.
    Bernard, John
    Siddani, Satya R.
    Parikh, Apurvasena
    Elliott, Brian
    Burkhardt, Birgit
    BLOOD, 2022, 140 : 3827 - 3828
  • [7] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Ryan, Christine E.
    Brander, Danielle M.
    Barr, Paul M.
    Tyekucheva, Svitlana
    Hackett, Liam R.
    Collins, Mary C.
    Fernandes, Stacey M.
    Ren, Yue
    Zhou, Yinglu
    McDonough, Mikaela M.
    Walker, Heather A.
    McEwan, Monica R.
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    LEUKEMIA, 2023, 37 (04) : 835 - 842
  • [8] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Christine E. Ryan
    Danielle M. Brander
    Paul M. Barr
    Svitlana Tyekucheva
    Liam R. Hackett
    Mary C. Collins
    Stacey M. Fernandes
    Yue Ren
    Yinglu Zhou
    Mikaela M. McDonough
    Heather A. Walker
    Monica R. McEwan
    Jeremy S. Abramson
    Eric D. Jacobsen
    Ann S. LaCasce
    David C. Fisher
    Jennifer R. Brown
    Matthew S. Davids
    Leukemia, 2023, 37 : 835 - 842
  • [9] Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    McKay, John
    Al-Juhaishi, Taha
    Lai Guanhua
    Kmieciak, Maciej
    Sabo, Roy
    Sindel, Ariel
    Yazbeck, Victor
    BLOOD, 2019, 134
  • [10] PHASE 1B STUDY OF IDELALISIB (GS-1101) PLUS CHLORAMBUCIL±RITUXIMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Barrientos, J.
    Leonard, J.
    Furman, R.
    Flinn, I.
    Vos, S.
    Coutre, S.
    Schreeder, M.
    Wagner-Johnston, N.
    Sharman, J.
    Boyd, T.
    Fowler, N.
    Kimii, Y.
    Holes, L.
    Johnson, D.
    Dansey, R.
    Dubowy, R.
    Rai, K.
    HAEMATOLOGICA, 2013, 98 : 42 - 43
12345